Biomarkers are tumour- or host-related factors that correlate with tumour biological behaviour and patient prognosis. High-throughput analytical techniques-DNA and RNA microarrays-have identified numerous possible biomarkers, but their relevance to melanoma progression, clinical outcome and the selection of optimal treatment strategies still needs to be established. The review discusses a possible molecular basis for predictive tissue biomarkers such as melanoma thickness, ulceration and mitotic activity, and provides a list of promising new biomarkers identified from tissue microarrays that needs confirmation by independent, prospectively collected clinical data sets. In addition, common predictive serum biomarkers-lactate dehydrogenase, S100B and melanoma-inhibiting activity-as well as selected investigational serum biomarkers such as TA90IC and YKL-40 are also reviewed. A more accurate, therapeutically predictive classification of human melanomas and selection of patient populations that would profit from therapeutic interventions are among the major challenges expected to be addressed in the future.

Additional Metadata
Keywords Biomarkers, LDH, Melanoma, MIA, S100
Persistent URL dx.doi.org/10.1093/annonc/mdp251, hdl.handle.net/1765/65728
Journal Annals of Oncology
Citation
Gogas, H, Eggermont, A.M.M, Hauschild, A, Hersey, P, Mohr, P, Schadendorf, D, … Dummer, R. (2009). Biomarkers in melanoma. Annals of Oncology, 20(SUPPL. 4). doi:10.1093/annonc/mdp251